SCHEMBL13618809

SCHEMBL13618809

CC(C)(C)NC(=O)CC(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
ALDH1A1 P00352 1/20 0.42
LDHA P00338 1/20 0.42
SRR Q9GZT4 1/20 0.42
POLB P06746 2/20 0.39
NPC1 O15118 2/20 0.39
LMNA P02545 2/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
GAA P10253 1/20 0.38
HMGCR P04035 1/20 0.38
CHRM1 P11229 1/20 0.38
TBXA2R P21731 1/20 0.38
ADRA1A P35348 1/20 0.38
NAALAD2 Q9Y3Q0 1/20 0.37
TSHR P16473 2/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18026348 0.85 ALDH1A1 (0.47) MAPTALDH1A1POLBNPC1LMNA
SCHEMBL2859890 0.79 PHF8 (0.50) MAPTALDH1A1POLBNPC1LMNA
SCHEMBL922696 0.78 ALDH1A1 (0.47) MAPTALDH1A1POLBNPC1LMNA
SCHEMBL19171550 0.77 SMN1; SMN2 (0.50) MAPTALDH1A1POLBNPC1LMNA
SCHEMBL12747921 0.76 ALDH1A1 (0.41) MAPTALDH1A1POLBNPC1LMNA
SCHEMBL5505398 0.76 ALDH1A1 (0.50) MAPTALDH1A1POLBNPC1LMNA
SCHEMBL8247619 0.75 SLC22A6 (0.50) MAPTALDH1A1LMNASMN1; SMN2NAALAD2
SCHEMBL155565 0.74
SCHEMBL1121578 0.74
SCHEMBL6356662 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023107863-A1 HETEROCYCLIC COMPOUNDS AS KIT KINASE INHIBITORS DECIPHERA PHARMACEUTICALS, LLC (US) 2023-06-15 WO disclosed
US-20180071262-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE ABBVIE INC. (US) 2018-03-15 US disclosed
US-20090286094-A1 Polyimide, polyamic acid and processes for the production thereof MITSUBISHI GAS CHEMICAL, INC. 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180071262-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE KAT2B, HDAC1, HDAC9 MAPT 650/4885ALDH1A1 601/4885LDHA 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.